ABUS

Arbutus Biopharma Stock Analysis

AI Rating

Good
  • Quality2/10
  • Growth↑ 9/10
  • Value↑ 6/10
Arbutus Biopharma sales and earnings growth
ABUS Growth
Great
  • Revenue Y/Y↑ 2828.78%
  • EPS Y/Y↑ 304.88%
  • FCF Y/Y↑ 42.42%
Arbutus Biopharma gross and profit margin trends
ABUS Profitability
Great
  • Gross margin ↑ 100.00%
  • EPS margin↑ 84.00%
  • ROIC 5Y↑ -48.98%
Arbutus Biopharma net debt vs free cash flow
ABUS Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 1869.8

Arbutus Biopharma stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks